ALLO - Allogene Therapeutics, Inc.
IEX Last Trade
2.17
0.075 3.456%
Share volume: 8,109
Last Updated: Fri 27 Dec 2024 05:30:26 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$2.10
0.08
3.58%
Fundamental analysis
12%
Profitability
0%
Dept financing
5%
Liquidity
75%
Performance
10%
Performance
5 Days
7.18%
1 Month
-17.06%
3 Months
-23.16%
6 Months
-10.68%
1 Year
-32.14%
2 Year
-62.81%
Key data
Stock price
$2.17
DAY RANGE
$2.06 - $2.22
52 WEEK RANGE
$1.92 - $5.78
52 WEEK CHANGE
-$36.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: David D. Chang
Region: US
Website: allogene.com
Employees: 310
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: allogene.com
Employees: 310
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Recent news